1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of mogamulizumab, an anti-CCR4 antibody targeting regulatory T cells in advanced cancer patients
    Meeting Abstract

    Plitas, G.; Wu, K.; Carlson, J.; Cimaglia, N.; Morrow, M.; Rudensky, A. Y.; Wolchok, J. D.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone
    Meeting Abstract

    Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity of anti -programmed death-1 (PD-1) agents in acral and mucosal melanoma
    Meeting Abstract

    Munhoz, R. R.; Shoushtari, A. N.; Kuk, D.; Ott, P. A.; Johnson, D. B.; Tsai, K. K.; Rapisuwon, S.; Eroglu, Z.; Sullivan, R. J.; Luke, J. J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
    Meeting Abstract

    Middleton, M. R.; Steven, N. M.; Evans, T. J.; Infante, J. R.; Sznol, M.; Mulatero, C.; Hamid, O.; Shoushtari, A. N.; Shingler, W.; Johnson, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI)
    Meeting Abstract

    Menzies, A. M.; Johnson, D. B.; Ramanujam, S.; Atkinson, V.; Wong, A. N. M.; Park, J. J.; McQuade, J. L.; Shoushtari, A. N.; Tsai, K. K.; Eroglu, Z.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identifying prognostic subgroups for outcomes in BRAF(V600)-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
    Meeting Abstract

    Larkin, J. M. G.; Ribas, A.; Flaherty, K.; McArthur, G. A.; Ascierto, P. A.; Dréno, B.; Lewis, K. D.; Chapman, P. B.; McKenna, E. F.; Zhu, Q.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors
    Meeting Abstract

    Koon, H. B.; Shepard, D. R.; Merghoub, T.; Schaer, D. A.; Sirard, C. A.; Wolchok, J. D.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069)
    Meeting Abstract

    Hodi, F. S.; Postow, M. A.; Chesney, J. A.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)
    Meeting Abstract

    Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save